A Maryland-based healthcare company is turning heads during Tuesday’s premarket after it was announced that the company said it saw “top line data from its successfully completed Unyvero UTI clinical trial.”
Shares of %Opgen () are currently bid up at $0.2297/share (+83.76% implied open for sellers) at the time of writing. This move will come just one session after the stock hit it’s 52-week low of $0.116 on Monday.
OpGen Inc is a %PrecisionMedicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The company's product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its curated MDRO knowledge base.